My Blue Dots

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per share. All of the shares are being offered by Amylyx. In addition, Amylyx has granted the underwriter a 30-day option to purchase up to an additional 2,571,428 shares of its common stock at the public offering price per share, less underwriting dis

DUBLIN–(BUSINESS WIRE)–The “Preclinical Contract Research Organizations – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Preclinical Contract Research Organizations was estimated at US$7.1 Billion in 2023 and is projected to reach US$11.3 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed bus

GLASGOW, Scotland–(BUSINESS WIRE)– #Chemify–Chemify hires biopharma veteran Dr. Alastair Leighton as Chief Operating Officer.

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025. “With our team’s innovation and execution throughout 2024, Rallybio is well positioned to create meaningful value in 2025,” said Stephen Uden, M.D., Chief Executive Officer of Rallybi

WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders. Key features of the

WATERTOWN, Mass.–(BUSINESS WIRE)–Addgene announces the expansion of its viral vector service with Packaged on Request.

SAN FRANCISCO & PRINCETON, N.J.–(BUSINESS WIRE)–Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve. “For decades, our team has observed significant treatment gaps across cardiovascular disease – from clinical care to investment in new medicines. While current standards of care play an important role, collect

MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624’s novel epigenetic mechanism of action on neurological pathways. The findings provide insights into the potential antidepressant and cognitive effects of SP-624, a SIRT6 activator that may be the first treatment specifically for females with Major Depression based on previous studies. Arrivo’s SP-624-103 study is a double blind, placebo-controlled study

BOULDER, Colo.–(BUSINESS WIRE)–Enveda, a biotechnology company using AI to translate life’s chemistry into new medicines, today announced the appointment of Jason Kim as Chief Financial Officer (CFO). Mr. Kim brings more than 20 years of biopharmaceutical corporate development and financial leadership experience to the Enveda team. In his new role, Mr. Kim will oversee Enveda’s financial strategy and operations, contributing to the company’s growth as it continues to develop innovative therap